[The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance].
To investigate the protein expression of ERCC1 (excision repair cross complementation group 1) and survivin gene in platinum-resistant and platinum-sensitive epithelial ovarian carcinoma (EOC), and to explore the relationship among ERCC1 expression, survivin expression, the major clinicopathological characteristics as well as platinum sensitivity. Expression of ERCC1 and survivin were detected in 64 EOC tissues by immunohistochemical method. No significant differences were found in patients' age, FIGO stage, pathological type, histological grade, pelvic lymph node and/or vessel infiltration, in all of three pairs of comparison. They were platinum-sensitive group vs. platinum-resistant group, ERCC1-positive group vs. ERCC1-negative group and surviving-positive group vs. survivn-negative group (all P > 0.05). The positive rate of ERCC1 expression (67.85%, 19/28) in platinum-resistant patients' tissues was significantly higher than that in platinum-sensitive patients' tissues (25.00%, 9/36) (P = 0.001). While the positive rate of survivin in platinum-resistant patients' tissues (78.57%, 22/28) was slightly higher than that of in platinum-sensitive patients' tissues (75.00%, 29/36), however without significant (P = 0.74). No evidence was found that the expression of ERCC1 correlate with the expression of survivin (r(s) = 0.12, P = 0.36) too. The proportion of platinum-resistant in patients with coexpression of ERCC1 and surviving (65.22%, 15/23) was insignificantly lower than that of in patients with single expression of ERCC1 (80.00%, 4/5) (P = 0.91). Expression of ERCC1 in EOC patients' tumor tissue could be a predictive indicator for their platinum susceptibility and it might be helpful for prevention and reverse of platinum resistance in clinical practice. The expression of survivin seems of no definite value in prediction of platinum susceptibility.